Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Clovis Oncology Announces European Commission Authorization of Rubraca (rucaparib) for Women with Recurrent Ovarian Cancer

firstwordpharmaMay 30, 2018

Tag: Clovis Oncology , European Commission , recurrent ovarian cancer

PharmaSources Customer Service